Devonian’s Thykamine Shows Strong Anti-Fibrotic Gene Effects in MASH Model

An announcement from Devonian Health Group ( (TSE:GSD) ) is now available.

Devonian Health Group reported new preclinical gene expression data from its STAM mouse model study of metabolic dysfunction–associated steatohepatitis, showing that orally administered Thykamine produced dose-dependent anti-MASH, anti-inflammatory and anti-fibrotic effects in the liver. The company said the therapy significantly down-regulated multiple fibrosis- and inflammation-related genes, in some cases by up to 80–90% versus placebo, providing molecular confirmation of previously observed histological benefits and further supporting Thykamine’s positioning as a multi-target, disease-modifying candidate for a broad range of inflammatory and hepatic disorders.

Researchers observed consistent pharmacological responses across 29 genes tied to liver fibrosis and inflammation, along with regional differences in drug activity between liver lobes, offering additional insight into Thykamine’s mechanism of action. Devonian plans to include the full gene expression dataset in a forthcoming scientific publication, a step that could bolster its scientific credibility and visibility in the rapidly growing global market for MASH treatments, where effective anti-fibrotic options remain limited.

More about Devonian Health Group

Devonian Health Group Inc. is a Québec-based clinical-stage biopharmaceutical company focused on developing novel therapies for fibroinflammatory diseases. Its lead candidate, Thykamine, is being advanced across multiple inflammatory indications, with emerging applications in hepatic conditions such as metabolic dysfunction–associated steatohepatitis (MASH), alongside existing programs in dermatology and inflammatory bowel disease.

Average Trading Volume: 821

Technical Sentiment Signal: Sell

Current Market Cap: C$27.66M

See more data about GSD stock on TipRanks’ Stock Analysis page.